RITA displays anti-tumor activity in medulloblastomas independent of TP53 status

Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40–70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP5...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Aline, Althoff, Kristina, Grunewald, Laura, Thor, Theresa, Odersky, Andrea, Schulte, Marc, Deubzer, Hedwig E., Heukamp, Lukas, Eggert, Angelika, Schramm, Alexander, Schulte, Johannes H., Künkele, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438615/
https://www.ncbi.nlm.nih.gov/pubmed/28427187
http://dx.doi.org/10.18632/oncotarget.15840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438615/
https://www.ncbi.nlm.nih.gov/pubmed/28427187
http://dx.doi.org/10.18632/oncotarget.15840

Ejemplares similares